NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert opinion on therapeutic targets

• Publication date

  2010-10-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14728222.2010.522570PMID 20858024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Azacitidine

  2012influential reference
• Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes

  2011cited by this paper
• Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation

  2010cited by this paper
• Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005)

  2010influential reference
• Lenalidomide in Myelodysplastic Syndromes: An Erythropoiesis-Stimulating Agent or More?

  2010cited by this paper
• Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

  2010cited by this paper
• Acute myeloid leukemia.

  2010cited by this paper
• Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.

  2010cited by this paper
• Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

  2010cited by this paper
• Distinct Combinatorial Effects of the Plant Polyphenols Curcumin, Carnosic Acid, and Silibinin on Proliferation and Apoptosis in Acute Myeloid Leukemia Cells

  2010cited by this paper
• Protein–protein interactions involving IKKγ (NEMO) that promote the activation of NF‐κB

  2010cited by this paper
• Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).

  2010cited by this paper
• The nuclear signaling of NF-κB: current knowledge, new insights, and future perspectives

  2010cited by this paper
• Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience

  2010cited by this paper
• Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  2010cited by this paper
• Immunity, inflammation, and cancer.

  2010cited by this paper
• NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction.

  2010cited by this paper
• Novel therapies for myelodysplastic syndromes.

  2010cited by this paper
• Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

  2010cited by this paper
• Myelodysplastic syndromes classification and risk stratification.

  2010cited by this paper
• Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib

  2010cited by this paper
• Ex vivo Inhibition of NF‐κB Signaling in Alloreactive T‐cells Prevents Graft‐Versus‐Host Disease

  2009cited by this paper
• IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines

  2009cited by this paper
• TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.

  2009cited by this paper
• Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

  2009cited by this paper
• ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2009cited by this paper
• Is NF-κB a good target for cancer therapy? Hopes and pitfalls

  2009cited by this paper
• Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)

  2009cited by this paper
• The protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

  2009cited by this paper
• Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.

  2009cited by this paper
• Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia

  2008influential reference
• Proteasome inhibition drastically but reversibly impairs murine lymphocyte development

  2008cited by this paper
• Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2008influential reference
• Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

  2008cited by this paper
• Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines

  2008cited by this paper
• Nuclear Factor-κB Modulation in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia

  2008cited by this paper
• Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.

  2008cited by this paper
• A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblasts

  2008cited by this paper
• Myelodysplastic syndromes.

  2008cited by this paper
• Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions–a review

  2008cited by this paper
• The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

  2008influential reference
• The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

  2007cited by this paper
• Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status

  2007influential reference
• Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling.

  2007cited by this paper
• Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein–Barr virus‐associated T‐cell lymphoma: Nuclear factor‐κB pathway as a potential therapeutic target

  2007influential reference
• Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy

  2007cited by this paper
• Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia

  2007cited by this paper
• Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.

  2007influential reference
• Nuclear factor κB as a target for new drug development in myeloid malignancies

  2007cited by this paper
• Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

  2007cited by this paper
• NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia.

  2007cited by this paper
• Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

  2007influential reference
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only.

  2007cited by this paper
• Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.

  2007cited by this paper
• Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia

  2007cited by this paper
• M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib‐mediated apoptosis

  2007influential reference
• Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells

  2007cited by this paper
• NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2007cited by this paper
• 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells

  2007cited by this paper
• Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia

  2007influential reference
• NF-kappaB as a potential molecular target for cancer therapy.

  2007cited by this paper
• NF‐κB as a potential molecular target for cancer therapy

  2007cited by this paper
• NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome.

  2006influential reference
• Targeting NF-kappaB in hematologic malignancies.

  2006cited by this paper
• Nuclear factor-κB in cancer development and progression

  2006cited by this paper
• Inhibitors of NF-κB signaling: 785 and counting

  2006cited by this paper
• Acute myeloid leukaemia.

  2006cited by this paper
• Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS

  2006cited by this paper
• NF-kappaB and IKK as therapeutic targets in cancer.

  2006cited by this paper
• NF-κB and IKK as therapeutic targets in cancer

  2006cited by this paper
• NF-κB inhibition: A double-edged sword in cancer?

  2006cited by this paper
• Targeting NF-κB in hematologic malignancies

  2006cited by this paper
• NF-kappaB inhibition: a double-edged sword in cancer?

  2006cited by this paper
• Inhibitors of NF-kappaB signaling: 785 and counting.

  2006influential reference
• Nuclear factor-kappaB in cancer development and progression.

  2006cited by this paper
• Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.

  2005cited by this paper
• Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.

  2005cited by this paper
• Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

  2005cited by this paper
• Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas

  2005cited by this paper
• Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas.

  2005cited by this paper
• The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment

  2005cited by this paper
• Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells

  2005cited by this paper
• IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy

  2005cited by this paper
• Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

  2005cited by this paper
• NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

  2005cited by this paper
• NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

  2005cited by this paper
• IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

  2005cited by this paper
• Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity.

  2005cited by this paper
• Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

  2004cited by this paper
• Constitutive NF-κB/Rel Activation in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

  2004cited by this paper
• Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.

  2004influential reference
• The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer

  2004cited by this paper
• Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

  2004cited by this paper
• Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide

  2004cited by this paper
• The IKK NF-κB system: a treasure trove for drug development

  2004cited by this paper
• The IKK NF-kappa B system: a treasure trove for drug development.

  2004cited by this paper

• Analysis of the Relationship Between NF-κB1 and Cytokine Gene Expression in Hematological Malignancy: Leveraging Explained Artificial Intelligence and Machine Learning for Small Dataset Insights

  2025influential citation
• A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML

  2023cites this paper
• DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias

  2023cites this paper
• Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia

  2022cites this paper
• SUMOylation controls the rapid transcriptional reprogramming induced by anthracyclines in Acute Myeloid Leukemias

  2022cites this paper
• TIM3/CEACAM1 pathway involves in myeloid‐derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome

  2022cites this paper
• Integrative genomic analysis of a novel small nucleolar RNAs prognostic signature in patients with acute myelocytic leukemia.

  2022cites this paper
• E3 ubiquitin ligases in the acute leukemic signaling pathways

  2022cites this paper
• 伴t(14;19)(q32;q13)小B淋巴细胞增殖性疾病20例临床分析

  2022cites this paper
• The molecular and clinical significance of the Tie/angiopoietin system in leukemia.

  2022cites this paper
• Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review

  2022cites this paper
• Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

  2021cites this paper
• Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2+ Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression

  2021cites this paper
• Integrated analysis of microRNA and transcription factors in the bone marrow of patients with acute monocytic leukemia

  2020cites this paper
• Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype

  2019cites this paper
• Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes.

  2019cites this paper
• Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes

  2018cites this paper
• Wogonin protects human retinal pigment epithelium cells from LPS-induced barrier dysfunction and inflammatory responses by regulating the TLR4/NF-κB signaling pathway.

  2017influential citation
• MicroRNA-22 controls interferon alpha production and erythroid maturation in response to infectious stress in mice.

  2017cites this paper
• THERAPEUTIC POTENTIAL OF TARGETING REACTIVE OXYGEN SPECIES (ROS) STRESS IN MYELODYSPLASTIC SYNDROME (MDS)

  2017cites this paper
• Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A

  2017cites this paper
• Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.

  2016cites this paper
• New insights into transfusion-related iron toxicity: Implications for the oncologist.

  2016cites this paper
• MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target

  2016cites this paper
• Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes

  2016cites this paper
• The oral iron chelator deferasirox inhibits NF‐κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia

  2015cites this paper
• Deconstructing innate immune signaling in myelodysplastic syndromes.

  2015cites this paper
• Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.

  2015influential citation
• Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia

  2015cites this paper
• Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling

  2015cites this paper
• Simultaneous assessment of NF-κB/p65 phosphorylation and nuclear localization using imaging flow cytometry.

  2015cites this paper
• Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.

  2015cites this paper
• KDM4B as a Target for Prostate Cancer: Structural Analysis and Selective Inhibition by a Novel Inhibitor

  2014cites this paper
• Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.

  2014cites this paper
• BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins

  2014cites this paper
• Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

  2013cites this paper
• CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.

  2013cites this paper
• Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway

  2013cites this paper
• A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth

  2013cites this paper
• Microarray analysis of NF-κB-dependent genes in chronic rhinosinusitis with nasal polyps.

  2013cites this paper
• Identification of MLL-A9 related target genes and microRNAs involved in leukemogenesis

  2012cites this paper
• Proteasome inhibitor bortezomib overcomes P‐gp‐mediated multidrug resistance in resistant leukemic cell lines

  2012cites this paper
• Regulation of NF-κB Activation through a Novel PI-3K-Independent and PKA/Akt-Dependent Pathway in Human Umbilical Vein Endothelial Cells

  2012cites this paper
• EGCG targeting efficacy of NF-κB downstream gene products is dictated by the monocytic/macrophagic differentiation status of promyelocytic leukemia cells

  2012cites this paper
• Demethoxycurcumin Retards Cell Growth and Induces Apoptosis in Human Brain Malignant Glioma GBM 8401 Cells

  2012cites this paper
• Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).

  2012cites this paper
• Imidazoline derivatives: a patent review (2006 – present)

  2012cites this paper
• A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes

  2012cites this paper
• Pulsing Electromagnetic Field and Death of Proliferating Peripheral Blood Mononuclear Cells from Patients with Acute Myelogenic Leukemia* Pulsacyjne pole elektromagnetyczne a śmierć komórkowa proliferujących leukocytów jednojądrzastych pochodzących od pacjentów z ostrą białaczką mieloidalną

  2011cites this paper
• The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks.

  2011cites this paper
• Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

  2011cites this paper
• Nuclear factor-kappa B inhibitors; a patent review (2006 – 2010)

  2011cites this paper
• Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity

  2010cites this paper